CoChat

UBE1L causes lung cancer growth suppression by targeting cyclin D1

Open access
Feng, Qing, Sekula, David, Guo, Yongli, Liu, Xi, Black, Candice C., Galimberti, Fabrizio, Shah, Sumit J., Sempere, Lorenzo F., Memoli, Vincent, Andersen, Jesper B., Hassel, Bret A., Dragnev, Konstantin, Dmitrovsky, Ethan · 2008 · Molecular Cancer Therapeutics
Cited by 82

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

UBE1L is the E1-like ubiquitin-activating enzyme for the IFN-stimulated gene, 15-kDa protein (ISG15). The UBE1L-ISG15 pathway was proposed previously to target lung carcinogenesis by inhibiting cyclin D1 expression. This study extends prior work by reporting that UBE1L promotes a complex between ISG15 and cyclin D1 and inhibited cyclin D1 but not other G1 cyclins. Transfection of the UBE1L-ISG15 deconjugase, ubiquitin-specific protein 18 (UBP43), antagonized UBE1L-dependent inhibition of cyclin D1 and ISG15-cyclin D1 conjugation. A lysine-less cyclin D1 species was resistant to these effects. UBE1L transfection reduced cyclin D1 protein but not mRNA expression. Cycloheximide treatment augmented this cyclin D1 protein instability. UBE1L knockdown increased cyclin D1 protein. UBE1L was independently retrovirally transduced into human bronchial epithelial and lung cancer cells. This reduced cyclin D1 expression and clonal cell growth. Treatment with the retinoid X receptor agonist bexarotene induced UBE1L and reduced cyclin D1 immunoblot expression. A proof-of-principle bexarotene clinical trial was independently examined for UBE1L, ISG15, cyclin D1, and Ki-67 immunohistochemical expression profiles in pretreatment versus post-treatment tumor biopsies. Increased UBE1L with reduced cyclin D1 and Ki-67 expression occurred in human lung cancer when a therapeutic bexarotene intratumoral level was achieved. Thus, a mechanism for UBE1L-mediated growth suppression was found by UBE1L-ISG15 preferentially inhibiting cyclin D1. Molecular therapeutic implications are discussed. [Mol Cancer Ther 2008;7(12):3780–8]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-08-0753

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 82

Metadata

Authors
Feng, Q., Sekula, D., Guo, Y., Liu, X., Black, C. C., Galimberti, F., Shah, S. J., Sempere, L. F., Memoli, V., Andersen, J. B., Hassel, B. A., Dragnev, K., & Dmitrovsky, E.
Venue
Molecular Cancer Therapeutics
Published
2008-12-01
Volume
7
Issue
12
Pages
3780-3788
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2117096084
Cited by
82
References
2
FWCI
1.61
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: UBE1L causes lung cancer growth suppression by targeting cyclin D1. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0753
The paper
Feng, Q., Sekula, D., Guo, Y., Liu, X., Black, C. C., Galimberti, F., Shah, S. J., Sempere, L. F., Memoli, V., Andersen, J. B., Hassel, B. A., Dragnev, K., & Dmitrovsky, E. (2008). UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0753

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.